Janus Henderson Group’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-1,798,634
| Closed | -$167M | – | 2741 |
|
|
2021
Q4 | $167M | Buy |
1,798,634
+561,482
| +45% | +$37M | 0.07% | 267 |
|
|
2021
Q3 | $73.7M | Buy |
1,237,152
+1,160,591
| +1,516% | +$68.6M | 0.03% | 440 |
|
|
2021
Q2 | $5.22M | Buy |
76,561
+19,166
| +33% | +$1.25M | ﹤0.01% | 1052 |
|
|
2021
Q1 | $3.98M | Buy |
57,395
+8,138
| +17% | +$626K | ﹤0.01% | 1049 |
|
|
2020
Q4 | $3.79M | Buy |
49,257
+26,839
| +120% | +$2.01M | ﹤0.01% | 1016 |
|
|
2020
Q3 | $1.68M | Buy |
22,418
+2,303
| +11% | +$154K | ﹤0.01% | 1081 |
|
|
2020
Q2 | $1.27M | Sell |
20,115
-2,434
| -11% | -$134K | ﹤0.01% | 1095 |
|
|
2020
Q1 | $947K | Buy |
22,549
+15,163
| +205% | +$695K | ﹤0.01% | 1107 |
|
|
2019
Q4 | $335K | Buy |
7,386
+104
| +1% | +$4.92K | ﹤0.01% | 1334 |
|
|
2019
Q3 | $333K | Buy |
7,282
+72
| +1% | +$4.05K | ﹤0.01% | 1329 |
|
|
2019
Q2 | $423K | Sell |
7,210
-1,592
| -18% | -$82.3K | ﹤0.01% | 1277 |
|
|
2019
Q1 | $395K | Buy |
8,802
+3,183
| +57% | +$146K | ﹤0.01% | 1260 |
|
|
2018
Q4 | $219K | Sell |
5,619
-2,303
| -29% | -$90.4K | ﹤0.01% | 1307 |
|
|
2018
Q3 | $365K | Buy |
7,922
+1,615
| +26% | +$65.5K | ﹤0.01% | 1354 |
|
|
2018
Q2 | $275K | Buy |
+6,307
| New | +$271K | ﹤0.01% | 1340 |
|
Janus Henderson Group's ARNA Position: Q1 2022 in Review
Janus Henderson Group sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 1,798,634 shares — an estimated $167M sold.
Janus Henderson Group first reported a position in ARNA in Q2 2018 and held it in 15 quarters. The position peaked at $167M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Janus Henderson Group reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Janus Henderson Group sold 1,798,634 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $167M.
- Janus Henderson Group first reported a position in Arena Pharmaceuticals Inc in Q2 2018 and held it in 15 quarters.
- Janus Henderson Group's Arena Pharmaceuticals Inc position peaked at $167M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Janus Henderson Group's 13F filing for Q1 2022, filed 16 May 2022.